Table 3.
Baseline characteristics of 2:1 case-matched cohort (sex, age ± 5 years, PS and duration on pembrolizumab ± 2 months) for Q3W and Q6W schedule.
| Case-Matched Cohort (n = 113) | Q3W n = 39 | Q6W n = 74 | p-Value |
|---|---|---|---|
| Age at diagnosis (median) years | 70 | 70 | 0.964 |
| Sex | 1.000 | ||
| Female | 15 (38.5%) | 29 (39.2%) | |
| Male | 24 (61.5%) | 45 (60.8%) | |
| Smoking status | 0.116 | ||
| Never | 1 (2.6%) | 2 (2.7%) | |
| Former | 28 (71.8%) | 59 (79.7%) | |
| Current | 7 (17.9%) | 13 (17.6%) | |
| Unknown | 3 (7.7%) | 0 (0%) | |
| Smoking (median) years | 40 | 40 | 0.688 |
| ECOG PS | 1.000 | ||
| 0–1 | 26 (66.7%) | 49 (66.2%) | |
| ≥2 | 13 (33.3%) | 25 (33.8%) | |
| Histology | 0.807 | ||
| Squamous | 7 (17.9%) | 16 (21.6%) | |
| Non-squamous | 32 (82.1%) | 58 (78.4%) |